The endometrial response to modulation of ligand-progesterone receptor pathways is reversible

Rohan R Chodankar, Chodankar RR, Rohan Chodankar, Murray A, Alison Murray, Nicol M, Moira Nicol, M Nicol, Lucy Whitaker, Lucy H R Whitaker, Alistair Williams, Alistair R W Williams, Williams ARW, Hilary O D Critchley, Hilary Critchley
Fertility and sterility · 2021 · vol. 116(3) , pp. 882–895 · doi:10.1016/j.fertnstert.2021.02.008 · PMID:33865567 · W3152833192
article OA: hybrid CC0 ⤵ 5 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Ulipristal acetate treatment altered endometrial gene expression and cell proliferation, with these changes reversing after treatment cessation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo study the impact of the progesterone receptor modulator (PRM), ulipristal acetate (UPA), on endometrial morphology and function.DesignCross-sectional.SettingUniversity Research Institute.Patient(s)Endometrial biopsies from 16 patients with heavy menstrual bleeding with a structurally normal uterus or in association with structural abnormalities identified on radiological imaging (fibroids, adenomyosis or a combination of fibroids and adenomyosis).Intervention(s)Participants received UPA (5 mg once daily) for three 12-week courses, each separated by 4 weeks without treatment.Main Outcome Measure(s)Gene expression by real-time quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and digital image analysis were analyzed to investigate the endometrial impact of modulation of progesterone receptor pathways upon expression of steroid receptors, steroid metabolizing enzymes, cell proliferation, and progesterone-regulated genes in the same patients at 3 time points: before, during, and after discontinuation of PRM treatment.Result(s)Ulipristal acetate treatment resulted in increased messenger ribonucleic acid (mRNA) levels of steroid receptors compared with pretreatment secretory endometrium; decreased mRNA levels of 17- and 11-beta-hydroxysteroid dehydrogenases compared with pretreatment proliferative endometrium and pretreatment secretory endometrium; reduced cell proliferation compared with pretreatment proliferative endometrium; and altered mRNA levels of progesterone-regulated genes. A strong consistency between immunohistochemistry-digital image analysis and real-time quantitative reverse transcription polymerase chain reaction results was evident. Alterations in the mRNA levels and endometrial morphology returned to a pretreatment phenotype after the cessation of PRM exposure.Conclusion(s)The endometrial impact of the modulation of progesterone receptor pathways with PRM (UPA) treatment is reversible.Clinical Trial Registration NumberUlipristal acetate versus conventional management of heavy menstrual bleeding (UCON) trial (EudraCT 2014-003408-65; REC14/LO/1602) To study the impact of the progesterone receptor modulator (PRM), ulipristal acetate (UPA), on endometrial morphology and function. Cross-sectional. University Research Institute. Endometrial biopsies from 16 patients with heavy menstrual bleeding with a structurally normal uterus or in association with structural abnormalities identified on radiological imaging (fibroids, adenomyosis or a combination of fibroids and adenomyosis). Participants received UPA (5 mg once daily) for three 12-week courses, each separated by 4 weeks without treatment. Gene expression by real-time quantitative reverse transcription polymerase chain reaction, immunohistochemistry, and digital image analysis were analyzed to investigate the endometrial impact of modulation of progesterone receptor pathways upon expression of steroid receptors, steroid metabolizing enzymes, cell proliferation, and progesterone-regulated genes in the same patients at 3 time points: before, during, and after discontinuation of PRM treatment. Ulipristal acetate treatment resulted in increased messenger ribonucleic acid (mRNA) levels of steroid receptors compared with pretreatment secretory endometrium; decreased mRNA levels of 17- and 11-beta-hydroxysteroid dehydrogenases compared with pretreatment proliferative endometrium and pretreatment secretory endometrium; reduced cell proliferation compared with pretreatment proliferative endometrium; and altered mRNA levels of progesterone-regulated genes. A strong consistency between immunohistochemistry-digital image analysis and real-time quantitative reverse transcription polymerase chain reaction results was evident. Alterations in the mRNA levels and endometrial morphology returned to a pretreatment phenotype after the cessation of PRM exposure. The endometrial impact of the modulation of progesterone receptor pathways with PRM (UPA) treatment is reversible.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Endometrium Leiomyoma Menorrhagia Norpregnadienes Receptors, Progesterone Uterine Neoplasms Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adult Cross-Sectional Studies Endometrium Endometrium Endometrium Female Gene Expression Regulation Humans Leiomyoma

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (47)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-18T06:10:16.649438+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:43.494969+00:00
License: CC0 · commercial use OK